Standard Biotools Inc (LAB) Stock Price, Quote & News

Company Profile

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well...

Industry: Medical Devices

Sector: Healthcare

Phone: 650 266 6000

Fax: 650 871 7152

Website: www.standardbio.com

Address:

2 Tower Place, Suite 2000, South San Francisco, United States

Iightning Dec. 4 at 11:54 PM

1ightning® Premium Options Alert (Actionable) Ticker: $LAB Contract: Dec 19 $1C Entry: 0.55 Exit: 0.75 Return: +35.65% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Estimize Dec. 4 at 12:15 PM

Wall St is expecting -0.05 EPS for $LAB Q4 [Reporting 02/18 AMC] http://www.estimize.com/intro/lab?chart=historical&metric_name=eps&utm_con

0 · Reply

Iightning Dec. 4 at 7:33 AM

1ightning® Premium Options Alert (Actionable) Ticker: $LAB Contract: Dec 19 $1C Entry: 0.45 Exit: 0.63 Return: +38.96% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Stanleydavidson Dec. 2 at 5:46 PM

$LAB major 10 million insider ceo buy $APLD $RXRX $MSTR $MARA $NOVO $LILY

0 · Reply

Stanleydavidson Dec. 2 at 4:58 PM

$LAB the boss bought 10 million us dollars 1,30 .... big move news on the way 2$3$

0 · Reply

Iightning Dec. 2 at 1:58 AM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $LAB **Contract:** Dec 19 $1C **Entry:** 0.41 **Exit:** 0.51 **Return:** **+23.10% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

beckphan08 Dec. 1 at 10:34 PM

$LAB ok, someone might be onto something now.

0 · Reply

beckphan08 Nov. 28 at 4:48 PM

$LAB the only people buying are Casdin. I’m still down 50% on a substantial investment. The numbers don’t lie. Maybe they know a sale could be coming.

0 · Reply

Gunter0054 Nov. 28 at 3:51 PM

$LAB amazing news , yet it barely moves . Why? Am I missing something?

0 · Reply

Xanderzzzzzzz Nov. 28 at 12:40 PM

$LAB https://www.tipranks.com/news/insider-trading/massive-stock-purchase-signals-confidence-in-standard-biotools-insider-trading

0 · Reply

Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry

Nov 10, 2025, 12:15 PM EST - 24 days ago

Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks

ILMN

Nov 4, 2025, 4:05 PM EST - 4 weeks ago

Standard BioTools Reports Third Quarter 2025 Financial Results

Oct 21, 2025, 7:00 AM EDT - 6 weeks ago

Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025

Sep 3, 2025, 9:15 AM EDT - 3 months ago

Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development

ILMN

Aug 11, 2025, 4:01 PM EDT - 4 months ago

Standard BioTools Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 4 months ago

Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study

Jul 21, 2025, 7:00 AM EDT - 4 months ago

Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

Jun 23, 2025, 7:13 AM EDT - 5 months ago

Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

ILMN

Jun 23, 2025, 7:05 AM EDT - 5 months ago

Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina

May 30, 2025, 7:00 AM EDT - 6 months ago

Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series

May 6, 2025, 8:08 PM EDT - 7 months ago

Standard BioTools Inc. (LAB) Q1 2025 Earnings Conference Call Transcript

May 6, 2025, 4:01 PM EDT - 7 months ago

Standard BioTools Reports First Quarter 2025 Financial Results

Apr 24, 2025, 7:00 AM EDT - 8 months ago

Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025

Apr 22, 2025, 7:00 AM EDT - 8 months ago

Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025

Feb 27, 2025, 4:01 PM EST - 10 months ago

Standard BioTools to Participate in Upcoming Investor Conferences

Feb 26, 2025, 9:44 PM EST - 10 months ago

Standard BioTools Inc. (LAB) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:01 PM EST - 10 months ago

Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 12, 2025, 7:00 AM EST - 10 months ago

Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025

Jan 13, 2025, 7:00 AM EST - 11 months ago

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue

Dec 19, 2024, 8:00 AM EST - 1 year ago

Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 7, 2024, 8:00 AM EST - 1 year ago

Standard BioTools Appoints Alex Kim as Chief Financial Officer

Oct 30, 2024, 7:10 PM EDT - 1 year ago

Standard BioTools Inc. (LAB) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 4:01 PM EDT - 1 year ago

Standard BioTools Reports Third Quarter 2024 Financial Results

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024

Aug 28, 2024, 8:58 AM EDT - 1 year ago

Standard BioTools And 2 Other Penny Stocks Executives Are Buying

Aug 27, 2024, 9:15 AM EDT - 1 year ago

Standard BioTools And 3 Other Stocks Under $3 Executives Are Buying

Jul 31, 2024, 8:34 PM EDT - 1 year ago

Standard BioTools Inc. (LAB) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 4:02 PM EDT - 1 year ago

Standard BioTools Announces Senior Leadership Changes

Jul 31, 2024, 4:01 PM EDT - 1 year ago

Standard BioTools Reports Second Quarter 2024 Financial Results

Jul 17, 2024, 8:01 AM EDT - 1 year ago

Standard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024

May 28, 2024, 4:01 PM EDT - 1 year ago

Standard BioTools Purchases the Carterra® LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan Customers

May 23, 2024, 9:17 AM EDT - 1 year ago

Lab Instrument Industry Update - New Commercial Entrants

AKYA BNGO CTKB DHR MASS OMIC QGEN

May 20, 2024, 8:00 AM EDT - 1 year ago

Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 11, 2024, 12:45 PM EDT - 1 year ago

Standard BioTools Inc. (LAB) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:01 PM EDT - 1 year ago

Standard BioTools Reports First Quarter 2024 Financial Results

Apr 25, 2024, 8:01 AM EDT - 1 year ago

Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth

Apr 8, 2024, 8:00 AM EDT - 1 year ago

Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging

Apr 3, 2024, 4:01 PM EDT - 1 year ago

Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research

Mar 18, 2024, 8:12 AM EDT - 1 year ago

Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock

Feb 28, 2024, 8:44 PM EST - 1 year ago

Standard BioTools Inc. (LAB) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 4:01 PM EST - 1 year ago

Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 14, 2024, 8:30 AM EST - 1 year ago

Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

Feb 7, 2024, 8:30 AM EST - 1 year ago

Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine

Jan 8, 2024, 8:30 AM EST - 2 years ago

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue

Jan 5, 2024, 8:46 AM EST - 2 years ago

Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools

Jan 4, 2024, 10:23 PM EST - 2 years ago

Standard BioTools Stockholders Approve Merger with SomaLogic

Jan 4, 2024, 9:44 PM EST - 2 years ago

SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting

Dec 31, 2023, 2:10 PM EST - 2 years ago

Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools

Dec 29, 2023, 7:10 PM EST - 2 years ago

Madryn Asset Management Highlights Increasing Public Shareholder Opposition to Value-Destructive SomaLogic Merger and Calls on Company to Make Additional Disclosures

Iightning Dec. 4 at 11:54 PM

1ightning® Premium Options Alert (Actionable) Ticker: $LAB Contract: Dec 19 $1C Entry: 0.55 Exit: 0.75 Return: +35.65% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Estimize Dec. 4 at 12:15 PM

Wall St is expecting -0.05 EPS for $LAB Q4 [Reporting 02/18 AMC] http://www.estimize.com/intro/lab?chart=historical&metric_name=eps&utm_con

0 · Reply

Iightning Dec. 4 at 7:33 AM

1ightning® Premium Options Alert (Actionable) Ticker: $LAB Contract: Dec 19 $1C Entry: 0.45 Exit: 0.63 Return: +38.96% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Stanleydavidson Dec. 2 at 5:46 PM

$LAB major 10 million insider ceo buy $APLD $RXRX $MSTR $MARA $NOVO $LILY

0 · Reply

Stanleydavidson Dec. 2 at 4:58 PM

$LAB the boss bought 10 million us dollars 1,30 .... big move news on the way 2$3$

0 · Reply

Iightning Dec. 2 at 1:58 AM

0 · Reply

beckphan08 Dec. 1 at 10:34 PM

$LAB ok, someone might be onto something now.

0 · Reply

beckphan08 Nov. 28 at 4:48 PM

$LAB the only people buying are Casdin. I’m still down 50% on a substantial investment. The numbers don’t lie. Maybe they know a sale could be coming.

0 · Reply

Gunter0054 Nov. 28 at 3:51 PM

$LAB amazing news , yet it barely moves . Why? Am I missing something?

0 · Reply

Xanderzzzzzzz Nov. 28 at 12:40 PM

$LAB https://www.tipranks.com/news/insider-trading/massive-stock-purchase-signals-confidence-in-standard-biotools-insider-trading

0 · Reply

AnonMav Nov. 27 at 2:57 PM

$LAB Who's buying: Casdin Partners (Director) Amount: $9.8 Million This fund has been buying non-stop, culminating in a nearly $10M buy. They are loading the boat. https://share.trendspider.com/chart/LAB/94993hk2s8p?_go=hs12h

0 · Reply

SmartMoneyTradez Nov. 27 at 12:53 AM

$LAB go time

0 · Reply

Jkpga Nov. 27 at 12:38 AM

$LAB big moves after hours !

0 · Reply

Xanderzzzzzzz Nov. 26 at 11:03 PM

$LAB

0 · Reply

beckphan08 Nov. 26 at 10:52 PM

$LAB someone buying this ?

0 · Reply

Iightning Nov. 26 at 4:53 AM

1ightning® Options Trade Alert (Actionable) | Buy $LAB Dec 19 $2 Call | Enter: $0.12 Exit: $0.23 | Profit: 86.35% ROI | https://1ightning.com

0 · Reply

SmartMoneyTradez Nov. 25 at 8:56 PM

$LAB Seemed like it was going to drop below 1,35 two hours ago but bulls are in total control. Consolidating atm

0 · Reply

Iightning Nov. 25 at 3:01 PM

1ightning® Options Trade Alert (Actionable) | Buy $LAB Dec 19 $2 Call | Enter: $0.12 Exit: $0.23 | Profit: 86.35% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 3:55 AM

1ightning® Options Trade Alert (Actionable) | Buy $LAB Dec 19 $2 Call | Enter: $0.12 Exit: $0.23 | Profit: 86.35% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 22 at 1:07 AM

1ightning® Options Trade Alert (Actionable) | Buy $LAB Dec 19 $2 Call | Enter: $0.08 Exit: $0.11 | Profit: 48.21% ROI | https://1ightning.com

0 · Reply

Xanderzzzzzzz Nov. 21 at 8:57 PM

$LAB

0 · Reply

Jkpga Nov. 21 at 8:55 PM

$LAB 🔥

0 · Reply

Market Cap	546.08M
Revenue (ttm)	174.43M
Net Income (ttm)	-138.89M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-79.63%
Debt to Equity Ratio	0.00

Volume	1,185,000
Avg Vol	1,778,700
Day's Range	N/A - N/A
Shares Out	384.57M
Stochastic %K	60%
Beta	1.24
Analysts	Sell
Price Target	$1.55